A53T-mutated Human alpha-Synuclein is Involved in Blood Glucose Regulation of Western Type Diet-fed Parkinson's Disease Mice

Magdalena Daurer^{1,2}, Roland Rabl¹, Heinrich Roemer², Birgit Hutter-Paier¹ ¹QPS Austria GmbH, Grambach, Austria; ²Karl-Franzens University of Graz, Institute of Zoology, Austria

BACKGROUND

Besides genetic modifications, diabetes PD, we focused on investigating the (PD). To better understand the impact of PD animal model, the A53T mouse. diabetes and obesity caused by diet and

and obesity have been suggested to be effects of a Western type diet (WTD) a risk factor for the development and that contains high fat and sucrose, as progression of Parkinson's Disease well as supplemented cholesterol on a

MATERIALS and METHODS

A53T mutated alpha-Synuclein (A53T) and non-transgenic littermates (NTG) starting at 3 months of age. Afterwards (CD) until the end of their life. To monitor on the diet.

Transgenic mice overexpressing human the animals' response to the diet, the food intake, and body weight were evaluated weekly. Additionally, glucose received a control diet (CD) for 2 weeks, metabolism was investigated using the intraperitoneal glucose tolerance test animals were fed a WTD or control diet (ipGTT) after 5, 11, 26, and 34 weeks



Experimental Setup of the ipGTT

SUMMARY and CONCLUSION

In summary, our findings add evidence human alpha-Synuclein on glucose

regulation. Further research on this topic indicating an impact of A53T-mutated might pave the road for new therapeutic approaches in the field of PD.

For more information about the model please visit: <u>www.qpsneuro.com</u> or send us an e-mail: office-austria@qps.com

© 2021 QPS. Confidential. All rights reserved.

RESULTS

Both, NTG and A53T mice on WTD had a higher caloric intake which resulted in an elevated weight gain compared to CD-fed control animals of both genotypes (Figure 2). Intriguingly, fasting blood glucose levels were increased only in NTG mice already as early as 5 and 26 weeks on the WTD (Figure 3). Injecting a glucose solution intraperitoneally led to higher blood glucose levels in WTD-fed A53T and NTG mice 5 and 11 weeks after starting the dietary intervention. However, after 26 weeks, only NTG mice demonstrated elevated glucose levels. After 34 weeks on the diet, none of the groups demonstrated elevated glucose levels in the ipGTT (Figure



evaluated by weekly weighing of provided and consumed food and subsequent data analysis. Body weight was recorded weekly (B) n: 9-12/group. Mean +/- SEM. */+p<0.05, **/++p<0.01, ***/+++p<0.001, two-way ANOVA followed by Bonferroni's *post hoc* test.



Figure 3. Fasting blood glucose levels in week 5, 11, 26, and 34. Before applying the glucose solution in the course of the ipGTT, blood glucose levels of fasted animals were evaluated in treatment week 5 (A), 11 (B), 26 (C), and 34 (D). n: 8-12/group. Mean +/- SEM. *p<0.05 two-way ANOVA followed by Bonferroni's post hoc test.

Figure 4. Blood glucose levels during experimental phase evaluated by ipGTTs. Animals' glucose metabolism was evaluated at baseline before starting the dietary intervention during habituation phase (light and dark blue bars) and in weeks 5 (A, B), 11 (C, D), 26 (E, F), and 34 (G, H). Blood glucose concentrations of each treatment group were compared to the respective glucose levels of the ipGTT performed at baseline during the habituation phase when all animals were fed with the CD. Note that animals tested at week 34 were not tested at baseline. n: 8-12/group. Mean +/- SEM. *p<0.05, **p<0.01, ***p<0.001 two-way ANOVA followed by Bonferroni's *post hoc* test. N/A: not available.

